Earnings summaries and quarterly performance for ANGIODYNAMICS.
Executive leadership at ANGIODYNAMICS.
James Clemmer
Detailed
President and Chief Executive Officer
CEO
Laura Piccinini
Detailed
Senior Vice President and General Manager, Cardiovascular and International
Lawrence Weiss
Detailed
Senior Vice President, Chief Legal Officer and Corporate Secretary
Stephen Trowbridge
Detailed
Executive Vice President and Chief Financial Officer
Warren Nighan
Detailed
Senior Vice President, Global Supply Chain, Quality and Regulatory Affairs
Board of directors at ANGIODYNAMICS.
Research analysts who have asked questions during ANGIODYNAMICS earnings calls.
Yi Chen
H.C. Wainwright & Co.
4 questions for ANGO
Also covers: APDN, BLFS, BLTE +22 more
John Young
Canaccord Genuity - Global Capital Markets
3 questions for ANGO
Also covers: CVRX, IRTC, LUNG +2 more
Jon Young
Canaccord Genuity Group Inc.
3 questions for ANGO
Also covers: CBLL
Steven Lichtman
Oppenheimer & Co. Inc.
3 questions for ANGO
Also covers: ALC, COO, DXCM +12 more
Eduardo Han
H.C. Wainwright & Co.
2 questions for ANGO
Frank Takkinen
Lake Street Capital Markets
2 questions for ANGO
Also covers: AORT, AXGN, BBNX +17 more
Recent press releases and 8-K filings for ANGO.
AngioDynamics Discusses Strategic Transformation and MedTech Growth at UBS Conference
ANGO
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- AngioDynamics is in the "sixth or seventh inning" of a strategic transformation, shifting its portfolio towards high-gross-margin MedTech products.
- The MedTech business, which previously constituted less than 17% of total revenue, now represents approximately 45% and is projected to become the largest segment in the next fiscal year.
- The company anticipates being adjusted EBITDA positive going forward and achieving cash flow positive status for the current fiscal year ending May 31.
- Key MedTech growth drivers include the Arion system for PAD, the AlphaVac/AngioVac mechanical thrombectomy systems (which saw 40% growth in Q1 and are projected to reach $50 million this year) , and the NanoKnife for intermediate-risk prostate cancer, supported by a new CPT1 code.
- AngioDynamics provided fiscal year 2026 guidance of 5-7% overall sales growth, with double-digit growth expected from the MedTech segment and 1-3% from the medical device segment.
Nov 10, 2025, 1:00 PM
AngioDynamics Reports Strong Q1 FY2026 Results, Raises Full-Year Guidance
ANGO
Earnings
Guidance Update
Revenue Acceleration/Inflection
- AngioDynamics reported strong Q1 FY2026 results, with total revenue increasing 12.2% to $75.7 million, primarily driven by a 26.1% growth in its med-tech segment to $35.3 million.
- Profitability improved, with a gross margin of 55.3% (up 90 basis points) and an adjusted net loss of $4.2 million, or $0.10 per share, compared to a $4.4 million loss in the prior year.
- Key med-tech products showed significant growth: Auryon revenue grew 20.1% to $16.5 million, mechanical thrombectomy revenue increased 41.2% to $11.3 million, and NanoKnife revenue rose 26.7% to $6.4 million.
- The company raised its fiscal year 2026 net sales guidance to $308 million to $313 million and its adjusted EBITDA guidance to $6 million to $10 million, reflecting confidence in continued growth.
- Strategic initiatives include expanding the mechanical thrombectomy sales force to 50 dedicated representatives and anticipating increased NanoKnife demand with the January 1 effective date of its CPT-1 code for prostate cancer treatment.
Oct 2, 2025, 12:00 PM
AngioDynamics Reports Strong Q1 FY 2026 Results and Raises Full-Year Guidance
ANGO
Earnings
Guidance Update
Revenue Acceleration/Inflection
- AngioDynamics reported Q1 FY 2026 net sales of $75.7 million, marking 12.2% year-over-year growth, driven by a 26.1% increase in the Med Tech segment to $35.3 million.
- The company achieved pro forma Adjusted EBITDA of $2.2 million in Q1 FY 2026, an improvement of $2.3 million from Q1 FY25, and maintained a strong balance sheet with $38.8 million in cash and zero debt.
- AngioDynamics raised its FY 2026 financial guidance, now projecting net sales between $308 million and $313 million and Adjusted EBITDA between +$6.0 million and $10.0 million.
- Within the Med Tech segment, key products showed significant growth in Q1 2026, with Auryon sales increasing 20.1% to $16.5 million, total mechanical thrombectomy sales rising 41.2% to $11.3 million, and NanoKnife sales up 26.7% to $6.4 million.
Oct 2, 2025, 12:00 PM
AngioDynamics Reports Strong Q1 2026 Financial Results and Raises Full-Year Guidance
ANGO
Earnings
Guidance Update
Revenue Acceleration/Inflection
- AngioDynamics reported fiscal year 2026 first quarter net sales of $75.7 million, driven by a 26.1% increase in Med Tech net sales to $35.3 million.
- For Q1 FY2026, the company achieved an Adjusted EBITDA of $2.2 million, an improvement from ($0.2) million in the prior year, and an Adjusted loss per share of $0.10.
- The company ended the quarter with $38.8 million in cash and cash equivalents and reiterated its expectation to be cash flow positive for the full fiscal year 2026.
- AngioDynamics raised its full-year FY 2026 guidance for net sales to $308 - $313 million, Med Tech net sales growth to 14% - 16%, Adjusted EBITDA to $6.0 - $10.0 million, and Adjusted EPS to ($0.33) \u2013 ($0.23).
Oct 2, 2025, 11:30 AM
AngioDynamics Discusses Strategic Transformation and FY26 Outlook
ANGO
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- AngioDynamics is undergoing a strategic transformation, shifting its focus to higher-margin, higher-growth areas within its Med Tech segment, which has achieved a 25% CAGR over the last five years.
- For fiscal year 2026, the company projects total revenue between $305 million and $310 million, with its high-growth Med Tech business expected to increase 12% to 15% year-over-year, while the Med Device segment is anticipated to remain roughly flat.
- The company expects to be cash flow positive for the full fiscal year 2026, despite an anticipated cash utilization of approximately $20 million in Q1 FY26, and does not plan to use its revolver.
- Key Med Tech products are expected to drive future growth, including AlphaVac and AngioVac, which are projected to generate over $50 million in revenue in FY26, and NanoKnife, which anticipates double-digit growth in probes following the implementation of a new CPT code on January 1, 2026.
Aug 12, 2025, 1:55 PM
AngioDynamics Secures New Revolving Credit Facility
ANGO
Debt Issuance
- AngioDynamics, Inc. entered into a new Credit Agreement on May 28, 2025, with JPMorgan Chase Bank, N.A., providing a $25 million secured revolving credit facility.
- The Revolving Facility has a maturity date of May 28, 2027.
- During an initial "Availability Block Period," the facility will be reduced by $5,000,000 until the company demonstrates a fixed charge coverage ratio greater than 1:10 to 1.00.
- The proceeds from the Revolving Facility are intended for working capital and general corporate needs of AngioDynamics and its subsidiaries.
- The Credit Agreement includes a financial covenant requiring AngioDynamics to maintain a fixed charge coverage ratio of not less than 1.05 to 1.00 after the Availability Block Period.
May 28, 2025, 12:00 AM
Quarterly earnings call transcripts for ANGIODYNAMICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more